Former Johnson & Johnson Executive Sophia Pan Joins MSD China as Head of Oncology Business

March 2,According to industry sources,Merck China announced,Pan Fangyue will officially join the company on March 9 as the head of the Oncology Division, reporting directly to the President of China and becoming a core member of the China Leadership Team, fully steering the development of MSD's oncology business in China.

Merck & Co.2Month26The announcement on the 1st shows,Oncology DivisionFormer Director Fan BoruiAs of3Month1Officially assumed the position of General Manager of India on [date], reporting directly to the President of the Asia-Pacific region, and becoming a core member of the Asia-Pacific leadership team.

Sophia Pan (潘昉玥) DepartureThe news about Johnson & Johnson's innovative pharmaceuticals is inAnnounced on February 25, The reason for leaving is to seek new external development opportunities.

Pan FangyueGraduated from Shanghai University of Finance and Economics, Ross School of Business at the University of Michigan, and Tuck School of Business at Dartmouth College. She previously worked in the management consulting department of PwC before entering the pharmaceuticals industry.

Pan Fangyue is responsible.Johnson & Johnson Innovative PharmaceuticalsDuring the Immunotherapy Business Unit period,The results are very impressive:The scale of the immunology team has doubled, with business maintaining strong growth of over 35% for two consecutive years, and multiple core indicators repeatedly reaching new highs.Core product Tremfya (Tremfya) Breaks through the 10 billion yuan scale, becoming Johnson & Johnson China's first non-oncology field“One billion single product.

Before joining Johnson & Johnson,Pan Fangyue also onceWorking atNovartis Pharmaceuticals, once served as the head of the marketing department for Novartis' key immunology product Cosentyx, and as the Senior Marketing Director of the Immunology, Hepatology, and Dermatology Business Unit at Novartis Pharmaceuticals (China).

Specific information is subject to the company's statement.